title: In vivo administration of tumor necrosis factor-alpha is associated with antiviral activity in human peripheral mononuclear cells.
abstract: Tumor necrosis factor-alpha (TNF-alpha) has a spectrum of biologic effects and has been shown to exert antiviral effects in fibroblasts in vitro. The in vivo administration of TNF-alpha (40-160 micrograms/m2 intravenously over 2 hr) and its effects on vesicular stomatitis virus (VSV) replication in peripheral blood mononuclear cells (PBMC) from patients with malignancy was investigated. Blood was obtained before, during, and after infusion. The PBMC were separated and infected with VSV at a multiplicity of infection of 0.005 plaque-forming units/cell and virus yields were determined 72 h later. The TNF-alpha inhibited VSV yields by as much as 99% in a dose-dependent manner with the inhibition initially observed during the first hour of infusion. Despite a rapid reduction in TNF-alpha serum levels, the higher doses still produced antiviral effects 4 hr after the infusion. Sera obtained at identical times had no interferon activity. Human gamma-interferon (25 micrograms/ml) added in vitro augmented the TNF-alpha-induced inhibitory activity in both magnitude and duration. Percentages of lymphocytes and monocytes in peripheral blood were reduced at 4 hr after TNF-alpha administration and the monocyte to lymphocyte ratio was diminished and temporally coincided with the loss of TNF-induced antiviral state. These data suggest that the in vivo administration of TNF has a direct inhibitory activity on VSV replication in human peripheral blood mononuclear cells that was enhanceable by gamma-interferon and possibly monocyte mediated.
authors.affiliation: Department of Internal Medicine, University of Texas Medical Branch, Galveston 77550.
authors.forename: M
authors.initials: M
authors.lastname: Nokta
authors.forename: D
authors.initials: D
authors.lastname: Matzke
authors.forename: M
authors.initials: M
authors.lastname: Jennings
authors.forename: E
authors.initials: E
authors.lastname: Schlick
authors.forename: P I
authors.initials: PI
authors.lastname: Nadler
authors.forename: R
authors.initials: R
authors.lastname: Pollard
mesh_terms: D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007372:Interferons / Q000097:blood / Q000494:pharmacology; D007963:Leukocytes, Mononuclear / Q000382:microbiology*; D008214:Lymphocytes / Q000166:cytology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology; D009369:Neoplasms / Q000097:blood*; D011863:Radioimmunoassay; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D014721:Vesicular stomatitis Indiana virus / Q000187:drug effects* / Q000502:physiology; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D014409:Tumor Necrosis Factor-alpha; D007372:Interferons